Immediate Impact

3 from Science/Nature 78 standout
Sub-graph 1 of 22

Citing Papers

Biomarkers in Cancer Detection, Diagnosis, and Prognosis
2023 Standout
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
2022 Standout
3 intermediate papers

Works of A. Stopeck being referenced

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
2008
Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis
2005

Author Peers

Author Last Decade Papers Cites
A. Stopeck 236 80 86 20 287
Loretta D’Onofrio 133 78 76 18 291
Marie‐Therese Haider 229 56 84 16 323
Songran Liu 141 91 73 27 317
Ferdinand Haslbauer 207 77 52 26 287
Issei Hirai 114 113 64 27 272
Shengyu Wu 119 67 67 26 314
Jewel Plummer Cobb 135 72 65 20 322
Congrong Liu 63 48 68 29 300
Pengfei Jiang 127 109 40 21 320
Valentina Magri 196 60 124 27 324

All Works

Loading papers...

Rankless by CCL
2026